An engineered Axl 'decoy receptor' effectively silences the Gas6-Axl signaling axis

Nature Chemical Biology

Volumn 10, Issue 11, 2014, Pages 977-983

  Kariolis, Mihalis S ^a   Miao, Yu Rebecca ^b   Jones, Douglas S ^a   Kapur, Shiven ^a   Mathews, Irimpan I ^c   Giaccia, Amato J ^b   Cochran, Jennifer R ^a  

^a Stanford University   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SLAC NATIONAL ACCELERATOR LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXL DECOY RECEPTOR; AXL RECEPTOR TYROSINE KINASE; CYTOKINE RECEPTOR; GROWTH ARREST SPECIFIC PROTEIN 6; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; GROWTH ARREST-SPECIFIC PROTEIN 6; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; ONCOPROTEIN; PROTEIN BINDING; SIGNAL PEPTIDE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DISEASE COURSE; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; HYDROGEN BOND; METASTASIS; NONHUMAN; PLASMA HALF LIFE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STABILITY; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; GENETIC ENGINEERING; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; MUTATION; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC ENGINEERING; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MODELS, MOLECULAR; MUTATION; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84924425611     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nCHeMBIO.1636     Document Type: Article

References (47)

1. Lemke, G. & Rothlin, C. V. Immunobiology of the TAM receptors. Nat. Rev. Immunol. 8, 327-336 (2008).
2. Li, Y. et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28, 3442-3455 (2009).
3. Zhang, Z. et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 44, 852-860 (2012).
4. Hong, J., Peng, D., Chen, Z., Sehdev, V. & Belkhiri, A. ABL regulation by AXL promotes cisplatin resistance in esophageal cancer. Cancer Res. 73, 331-340 (2013).
5. Byers, L. A. et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 19, 279-290 (2013).
6. Vajkoczy, P. et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc. Natl. Acad. Sci. USA 103, 5799-5804 (2006).
7. Linger, R. M., Keating, A. K., Earp, H. S. & Graham, D. K. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv. Cancer Res. 100, 35-83 (2008).
8. Gustafsson, A. et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin. Cancer Res. 15, 4742-4749 (2009).
9. Chen, P. X., Li, Q. Y. & Yang, Z. Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma. Ann. Diagn. Pathol. 17, 425-429 (2013).
10. Rankin, E. B. et al. AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res. 70, 7570-7579 (2010).
11. Holland, S. J. et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer Res. 70, 1544-1554 (2010).
12. Yan, S. B. et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. Invest. New Drugs 31, 833-844 (2013).
13. Ye, X. et al. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29, 5254-5264 (2010).
14. Leconet, W. et al. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. Oncogene doi:10.1038/onc.2013.487 (2013).
15. Cerchia, L. et al. Targeting Axl with an high-affinity inhibitory aptamer. Mol. Ther. 20, 2291-2303 (2012).
16. Paolino, M. et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507, 508-512 (2014).
17. Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23, 329-336 (2005).
18. Fisher, P. W. et al. A novel site contributing to growth-arrest-specific gene 6 binding to its receptors as revealed by a human monoclonal antibody. Biochem. J. 387, 727-735 (2005).
19. Varnum, B. C. et al. Axl receptor tyrosine kinase stimulated by the vitamin-K-dependent protein encoded by growth-arrest-specific gene-6. Nature 373, 623-626 (1995).
20. Meyer, A. S., Miller, M. A., Gertler, F. B. & Lauffenburger, D. A. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci. Signal. 6, ra66 (2013).
21. Kariolis, M. S., Kapur, S. & Cochran, J. R. Beyond antibodies: using biological principles to guide the development of next-generation protein therapeutics. Curr. Opin. Biotechnol. 24, 1072-1077 (2013).
22. Economides, A. N. et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 9, 47-52 (2003).
23. Peppel, K., Crawford, D. & Beutler, B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174, 1483-1489 (1991).
24. Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99, 11393-11398 (2002).
25. Sasaki, T. et al. Structural basis for Gas6-Axl signalling. EMBO J. 25, 80-87 (2006).
26. Darling, R. J. & Brault, P. A. Kinetic exclusion assay technology: characterization of molecular interactions. Assay Drug Dev. Technol. 2, 647-657 (2004).
27. Hafizi, S. & Dahlback, B. Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS J. 273, 5231-5244 (2006).
28. Manfioletti, G., Brancolini, C., Avanzi, G. & Schneider, C. The protein encoded by a growth arrest-specific gene (gas6) is a new member of the vitamin K-dependent proteins related to protein S, a negative coregulator in the blood coagulation cascade. Mol. Cell. Biol. 13, 4976-4985 (1993).
29. Sasaki, T. et al. Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6-receptor tyrosine kinase activation by laminin G-like domains. J. Biol. Chem. 277, 44164-44170 (2002).
30. Chakrabartty, A., Doig, A. J. & Baldwin, R. L. Helix capping propensities in peptides parallel those in proteins. Proc. Natl. Acad. Sci. USA 90, 11332-11336 (1993).
31. Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484, 529-533 (2012).
32. Marshall, S. A., Lazar, G. A., Chirino, A. J. & Desjarlais, J. R. Rational design and engineering of therapeutic proteins. Drug Discov. Today 8, 212-221 (2003).
33. Gjerdrum, C. et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc. Natl. Acad. Sci. USA 107, 1124-1129 (2010).
34. Aslakson, C. J. & Miller, F. R. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399-1405 (1992).
35. Wan, L., Pantel, K. & Kang, Y. Tumor metastasis: moving new biological insights into the clinic. Nat. Med. 19, 1450-1464 (2013).
36. Lu, Q. et al. Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature 398, 723-728 (1999).
37. Angelillo-Scherrer, A. et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat. Med. 7, 215-221 (2001).
38. Paolino, M. et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507, 508-512 (2014).
39. Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553-557 (1997).
40. Chao, G. et al. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 1, 755-768 (2006).
41. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
42. Vagin, A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22-25 (2010).
43. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
44. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
45. The PyMOL Molecular Graphics System. Version 1.3r1, Schrödinger, LLC (2010).
46. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007).
47. Yuan, Z., Zhao, J. & Wang, Z. X. Flexibility analysis of enzyme active sites by crystallographic temperature factors. Protein Eng. 16, 109-114 (2003).